Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information: Administrative Supplement Study

Phase 2 Completed NCT06975085

Summary

The Understanding and Addressing Rejection of Personalized Cancer Risk Information study is a longitudinal study conducted to understand the nature of phenomenon of personalized cancer risk rejection in the context of mammography screening.

Number of Participants Who Rejected the Cancer Risk Estimate

at baseline survey · Participants

Risk-concordant Information Seeking

at baseline survey · Participants

Screening Intentions

at baseline survey · Participants

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Vitamin D and Physical Activity on Bone Health — University of Rochester
• Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in T — National Cancer Institute (NCI)
• Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor — National Cancer Institute (NCI)
• Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced — National Cancer Institute (NCI)
• A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Can — AstraZeneca
• Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer — National Cancer Institute (NCI)

All trials